stockrow
Friday 6 November 2026
Export BEAM’s income statement to Excel — free account
Beam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
26.35
0.48
+1.86%
Follow BEAM
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
17.46 | 22.95 | 15.00 | 19.62 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(23.11) | (54.17) | (19.15) | (32.92) | |
P/B ratio |
2.69 | 3.35 | 2.11 | 2.21 | |
Price to Tangible BV |
2.69 | 3.35 | 2.11 | 2.21 | |
EV/Sales |
11.02 | 16.20 | 8.23 | 11.86 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.16) | (7.03) | (3.65) | (4.80) | |
EV/FCF |
(4.06) | (6.78) | (3.52) | (4.60) | |
Quick Ratio |
12.72 | 14.25 | 16.25 | 12.85 | |
Current Ratio |
13.00 | 14.57 | 16.99 | 13.09 | |
Net Debt/EBITDA |
6.81 | 8.51 | 10.65 | 82.82 | |
Debt/Assets |
7.91% | 7.23% | 6.77% | 0.00% | |
Debt/Equity |
0.11 | 0.09 | 0.09 | 0.00 | |
Asset Turnover |
0.11 | 0.11 | 0.11 | 0.11 | |
Operating CF/Net income |
0.82 | 0.54 | 1.36 | (0.34) | |
Capex/Depreciation |
(0.45) | (0.84) | (0.78) | (1.55) | |
Research and Development Expense of Revenue |
35,866.45% | 19,407.35% | 329.33% | 87.00% | |
Selling, General and Administrative Expense of Revenue |
10,266.78% | 6,519.80% | 108.48% | 28.29% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
6,043.97% | 3,934.29% | 60.00% | 17.92% | |
Graham Net Nets |
0.29 | 0.24 | 0.39 | 0.37 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.11%) | (2.39%) | (2.69%) | (3.50%) | |
Free Cash Flow Yield |
(15.56%) | (10.41%) | (15.60%) | (13.13%) | |
Revenue per Share |
0.00 | 0.00 | 0.31 | 1.15 | |
Operating CF per Share |
(1.06) | (0.63) | (1.24) | (0.84) | |
Capex per Share |
(0.01) | (0.02) | (0.02) | (0.04) | |
Free Cash Flow per Share |
(1.07) | (0.66) | (1.27) | (0.88) | |
Cash per Share |
9.97 | 11.05 | 11.73 | 12.59 | |
Shareholders Equity per Share |
9.10 | 10.23 | 11.28 | 12.52 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.10 | 10.23 | 11.28 | 12.52 | |
Free Cash Flow |
(111.96) | (68.51) | (130.74) | (87.02) | |
Working Capital |
985.30 | 1,097.71 | 1,192.39 | 1,171.75 | |
Capital Expenditures |
(1.21) | (2.41) | (2.23) | (3.73) | |
Net Current Asset Value |
750.98 | 859.68 | 950.59 | 1,025.87 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
3.94 | 4.93 | 0.07 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
14.85 | 11.83 | 9.99 | 7.05 | |
Average Assets |
1,290.08 | 1,388.76 | 1,473.86 | 1,292.50 | |
Average Common Equity |
959.34 | 1,057.13 | 1,143.79 | 985.95 |
Columns are period end dates · fundamentals updated 5 Nov 2026